Treatment of IPF without nintedanib or pirfenidone
Treatment of IPF without nintedanib or pirfenidone
2016-06-10
Luca Richeldi
0:00
/
0:00
Loaded: 0%
0:00
Progress: 0%
Stream TypeLIVE
0:00
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
What treatment would you recommend in a patient with idiopathic pulmonary fibrosis who cannot be treated with nintedanib or pirfenidone?
Luca Richeldi:
Of course it is a problem because the only two drugs that have been shown to be safe and effective are pirfenidone and nintedanib. The current guidelines also provide conditional recommendations, based on low-quality evidence, for antacid medications. So according to the current guidelines, that is an option.
See also
Sedation in patients on noninvasive ventilation
What is your opinion on sedation of patients on noninvasive ventilation? In BTS guidelines, sedation with morphine is an optional approach in agitated patients receiving NIV.
Testing for latent TB infection in vaccinated populations
In Poland, a significant proportion of cases of tuberculosis (TB) is latent TB infection, and most of the population has been vaccinated against TB. Is there still a place for tuberculin skin testing or should it be replaced with IGRAs?
Nintedanib and pirfenidone in patients with FVC <50%
What is your opinion on using nintedanib and pirfenidone in patients with forced vital capacity <50%? Are there any data available to support such treatment?
English
Polski
Español
українська
